Background
==========

Discovering safe, novel immunomodulators that are effective in RA is currently a major therapeutic objective. Long-term immune system deviation is most striking in the host--parasite relationship, in which microbes may coexist with a human host.

Objective
=========

We have investigated our previously discovered filarial derived ES-62 for therapeutic potential in RA.

Methods
=======

ES-62 was administered during collagen-induced arthritis (CIA) either at immunization (prophylactic) or 24 hours after the onset of clinically evident disease (therapeutic). Cytokine and antibody responses were measured in *ex vivo* cultures. RA synovial cultures were also made.

Results
=======

ES-62 exhibited powerful immunomodulation of CIA, preventing initiation of inflammatory arthritis. Crucially, ES-62 suppressed even established disease. These effects were due to inhibition of cytokine release, specifically TNF-α, and reversal of collagen specific Th1 responses associated with reduced expression of IFN-γ. The physiologic relevance of these observations was confirmed, as ES-62 down-regulated the release of proinflammatory cytokines (TNF-α and IL-6) from patient-derived samples.

Conclusion
==========

The host--parasite relationship has long promised therapeutic potential. Our data clearly show that ES-62, a filarial-derived moiety, can profoundly alter cytokine expression *in vitro* and *in vivo* in inflammatory arthritis. This in turn suggests an intriguing role for ES-62 in treating chronic inflammatory diseases. Finally, our data have implications for the mechanisms that might underpin previously reported epidemiologic interactions between chronic infection and autoimmunity.
